Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.88) by 65.91 percent. This is a 114.71 percent decrease over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $78.000 thousand which missed the analyst consensus estimate of $99.833 thousand by 21.87 percent. This is a 92.91 percent decrease over sales of $1.100 million the same period last year.